---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-044286"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T06:49:03.554418+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M

## Summary
- Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.
- Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.
- Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.
- Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001213900-25-044286
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/0001213900-25-044286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/ea0242203-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-044286
- JSON: https://secwatch.observer/filing/0001213900-25-044286.json
- Plain text: https://secwatch.observer/filing/0001213900-25-044286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.